Variant · Snv
SMARCA2 K755R
CI-VAR-00002178Explore in graph →CIViC 4319
Curated evidence
Evidence by cancer (1 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 31375262
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Unmapped disease1unmapped disease | ||||||||
| SMARCA2 K755R | (functional) | Functional | D | Supports Neomorphic | 3 | accepted | EID11043SMARCA2 mutations K755R and R1159Q are seen in Nicolaides-Barraitser syndrome (NCBRS) (PMID: 22366787). To evaluate the effects of these mutations, CRISPR/Cas9 was used to introduce heterozygous K755R… (full text at CIViC) PMID 31375262 · Gao et al., 2019 · Open in CIViC | civic |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available
No ClinVar interpretation attached to this variant.